Pro to the question "Should Prescription Drugs Be Advertised Directly to Consumers?"
"AstraZeneca believes responsible direct-to-consumer (DTC) advertising is integral to raising disease awareness, fostering patient education, enhancing the patient/physician dialogue and encouraging medication adherence. And we also recognize that consumers today need to be engaged differently. Ads need to be both informative and compelling to make a lasting impression and to effectively raise awareness of an issue or a treatment."
Rod Wooten, "AstraZeneca Takes a New Advertising Approach to Engage & Educate Consumers," www.azhealthconnections.com, Oct. 1, 2013
Organizations/VIPs/Others Individuals and organizations that do not fit into the other star categories.
"For patients and physicians, we provide medicines for some of the world's most serious diseases. For the people who pay for health care, we work to make sure that our medicines offer real value for money. For our employees, we provide a culture in which they can feel appreciated, energized and rewarded for their contribution. For our shareholders, we aim to deliver value through our continued focus on innovation and running our business efficiently. For the wider community, we want to be valued for the contribution our medicines can make to society and trusted for the way in which we do business.
We work closely with all our stakeholders to understand their challenges and how we can combine our skills and resources to achieve a common goal: improved health."
"About Us," www.astrazeneca-us.com (accessed Mar. 12, 2014)
"AstraZeneca is a global biopharmaceutical company with research and development at its core.
Our mission is to make a meaningful difference to healthcare through great medicines. This is founded on the pursuit of scientific excellence that addresses unmet patient need.
Our expertise spans the entire life-cycle of a medicine and we have capabilities in both small molecules and biologics. This allows us to search for solutions to unmet medical needs using both modalities, individually or in combination."
"Research," www.astrazeneca-us.com (accessed Mar. 12, 2014)
Not membership or subscription based
$53.53 billion (AstraZeneca total assets as of Dec. 31, 2012)
Pascal Soriot, CEO
# of Offices:
Offices in over 100 countries (headquarters in London, England)
# of Staff:
About 50,000 employees worldwide
Bristol-Meyers Squibb, acquired by AstraZeneca on Feb. 3, 2014
MedImmune, AstraZeneca's global biologics and research arm
Immunocore, private UK biotechnology company
Janssen Pharmaceuticals K.K., Japan, alliance to promote prostate cancer treatment
Merck & Co., Inc., agreement to investigate cancer drug, MSD
FibroGen, collaboration to develop and commercialize FG-4592, an anemia treatment for people with severe kidney disease
Pearl Therapeutics, acquired by AstraZeneca on June 28, 2013
Alchemia Limited, drug discovery and development collaboration
Vanderbilt University, collaboration to develop brain disorder treatments
Fundan University, China, research collaboration
Isis Pharmaceuticals, strategic alliance to develop RNA therapeutics
Roche Diagnostics, collaboration to advance personalized healthcare
Pfizer, agreement for OTC Nexium
Medical Research Council (MRC), UK, research collaboration
Daichi Sankyo, Japan, agreement to co-promote cancer drug, Denosumab